Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Operating Expenses (2022 - 2025)

Historic Operating Expenses for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $85.7 million.

  • ARS Pharmaceuticals' Operating Expenses rose 25981.27% to $85.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.6 million, marking a year-over-year increase of 27029.2%. This contributed to the annual value of $92.2 million for FY2024, which is 3653.89% up from last year.
  • ARS Pharmaceuticals' Operating Expenses amounted to $85.7 million in Q3 2025, which was up 25981.27% from $63.3 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Operating Expenses' 5-year high stood at $85.7 million during Q3 2025, with a 5-year trough of $6.8 million in Q2 2022.
  • For the 4-year period, ARS Pharmaceuticals' Operating Expenses averaged around $26.1 million, with its median value being $18.0 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 3378.23% in 2023, then skyrocketed by 29981.69% in 2025.
  • Over the past 4 years, ARS Pharmaceuticals' Operating Expenses (Quarter) stood at $15.4 million in 2022, then tumbled by 33.78% to $10.2 million in 2023, then skyrocketed by 285.14% to $39.4 million in 2024, then surged by 117.58% to $85.7 million in 2025.
  • Its Operating Expenses stands at $85.7 million for Q3 2025, versus $63.3 million for Q2 2025 and $45.2 million for Q1 2025.